A comparative study of two different doses of dexmedetomedine as an adjuvant to lignocaine in infiltration block for tympanoplasty: a triple-blinded, prospective, randomized controlled trial

Article information

Anesth Pain Med. 2024;19(4):310-319
Publication date (electronic) : 2024 October 31
doi : https://doi.org/10.17085/apm.24105
Department of Anaesthesiology, Indira Gandhi Institute of Medical Sciences, Patna, India
Corresponding author: Annu Choudhary, M.D. Department of Anaesthesiology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, Pin-800010, India. Tel: 0612-2297099 E-mail: anucdry@gmail.com
Received 2024 July 13; Revised 2024 September 25; Accepted 2024 September 26.

Abstract

Background

The ideal anesthetic drug choice for local infiltration anesthesia under monitored anesthesia care must provide analgesia and patients' comfort along with a bloodless surgical field for patients. We hypothesized that dexemedetomidine can provide better visibility of the surgical field at a higher dose of 1 µg/kg than 0.5 µg/kg, along with providing sedation and analgesia.

Methods

After institutional ethics committee clearance and written informed consent, this prospective, randomized, triple blind study was conducted on ninety patients, between 18-65 years who were scheduled for tympanoplasty. The patients were randomly assigned to either the dexmedetomidine (DEX) 0.5 group or the DEX 1.0 group, and received 10 ml solution containing 2% lignocaine with 0.5 µg/kg dexmedetomidine, or the 1 µg/kg dexmedetomidine. The operative surgeon performed local infiltration using standardized 5-point infiltration technique around the auricle. The primary objective was to compare the intraoperative bleeding at the surgical site. The comparison of normally distributed variables was conducted using the Student's t-test, whereas non-normally distributed variables was compared using the Mann-Whitney U test. The analysis of qualitative data was conducted using the chi-square/Fisher's exact test. A P value less than 0.05 was considered statistically significant.

Results

The overall bleeding score was significantly higher in the DEX 0.5 group (3.21 ± 0.727) than the DEX 1.0 group (1.43 ± 0.661) (P value < 0.001). The time to first analgesic requirement and surgeon satisfaction score were also significantly higher in the DEX 1.0 group.

Conclusions

Combining dexmedetomidine at a dose of 1 µg/kg with 2% lignocaine for infiltration provided improved analgesia and improved the surgical field during tympanoplasty performed under monitored anesthesia care.

INTRODUCTION

The choice of anesthesia for specific operations can vary greatly based on the country, hospital protocols, and the preferences of both the surgeon and anesthesiologist. For tympanoplasty, general anesthesia or locoregional anesthesia can be employed, with or without sedation [1]. Locoregional anesthesia has several advantages, like patient cooperation during facial nerve monitoring, intraoperative hearing testing, faster recovery, and early discharge. In addition to anesthesia, another requirement during the surgery is a bloodless surgical field. Local infiltration with a local anesthetic and adrenaline combination is most frequently used to provide an optimum surgical field. However, as adrenaline is absorbed into the body, it can cause several harmful side effects. Therefore, a substitute of adrenaline is required to provide similar conditions but with minimal side effects.

Dexmedetomidine (DEX) has been approved to be used as an adjuvant through the intravenous route. Various previous studies have shown multiple benefits of DEX as an intravenous adjuvant in dose, ranging from 0.5 µg/kg to 3 µg/kg [2-4]. Other routes of DEX administration are also being explored. Several research investigations have been conducted to compare the effectiveness of adrenaline and DEX as adjuvants with local anesthetics for infiltration in various surgical procedures [5,6]. Ouchi et al. [7] found that DEX enhances the local anesthetic action of lidocaine in a dose-dependent manner in a rat TF model. Other beneficial dose-dependent effects of DEX are sedation, analgesia, sympatholytic action, and reduced anxiety without respiratory depression or wide hemodynamic fluctuation.

Local use of DEX as an adjuvant can reduce its systemic side effects, such as dry mouth, bradycardia and hypotension risk, and deep sedation. Research conducted on both animals and humans has put forth several hypotheses to elucidate its localized impact, although the precise mechanism remains uncertain. In addition, its effect on the 2-beta receptor in smooth muscle cells of the peripheral blood vessels might cause the capillaries to constrict, resulting in a decrease in blood loss and absorption of local anesthetic. Several trials have administered it locally together with LA at varying doses (ranging from 0.5 µg/kg to 5 µg/kg) for a variety of surgical procedures [8-10].

There is a gap in the literature regarding a safe dose of DEX for optimum effect when used as an adjuvant to a local anesthetic to be used for tympanoplasty. Our hypothesis was that administering a higher dose of DEX would result in both a localized effect and systemic benefits. Therefore, we conducted this study to compare two standard doses of DEX in order to achieve a bloodless surgical field while minimizing adverse effects. The primary objective of this study was to compare the intraoperative bleeding at the surgical site with the use of 0.5 µg/kg and 1 µg/kg DEX with 2% lidocaine for local infiltration. The secondary objectives were time of first analgesia requirement, degree of sedation, surgeons’ satisfaction, and intraoperative hemodynamics.

MATERIALS AND METHODS

A prospective, randomized, controlled, triple-blinded study was designed in a tertiary care center. This trial was approved by the institutional ethics committee (1064/1EC/IGIMS/2023) and registered at the Clinical Trials Registry-India, www.ctri.nic.in (CTRI/2023/09/057450, September 11, 2023). The study enrolled patients between October 2023 and January 2024, adhering to the principles of the Declaration of Helsinki (2013) and good clinical practice.

The study enrolled patients between the ages of 18 and 65, with physical statuses I to II according to the American Society of Anesthesiologists, scheduled for tympanoplasty under local infiltrative block and under monitored anesthesia care. Exclusion criteria were patient refusal, severe cardiopulmonary diseases, allergy to local anesthetics, inability to communicate and cooperate, or infection at the surgical site.

After preoperative screening for eligibility, written informed consent was obtained. According to computer-generated codes, using the permuted block randomization method with a block size of eight, patients were randomized to two equal groups by sequentially numbered, sealed opaque envelopes, which were opened after recording of baseline parameters. Patients in DEX 0.5 group received 10 ml of 2% lignocaine with 0.5 µg/kg DEX, and in DEX 1.0 group, patients received 10 ml of 2% lignocaine with 1 µg/kg DEX. The dosage of DEX was determined based on the patient's body weight and estimated using the Broca method if the patient weighed more than 100 kg. The patient, the surgeon administering the local anesthetic, and the anesthesiologist assessing the patient intraoperatively were blinded to group allocation. An anesthesia resident not involved in the study prepared the drug for infiltration in a 10 ml syringe.

After securing 18-gauge peripheral venous access and applying American Society of Anesthesiologists standard monitors (pulse oximetry, noninvasive blood pressure, electrocardiogram, temperature), the baseline parameters were recorded. Then, patients were handed over to the surgeon for local infiltration with the drug prepared according to the group randomization. The technique of infiltration was standardized by administering 2 ml of fluid at each of the five points around the auricle using 26-gauge needles (Fig. 1) [11]. All hemodynamic parameters were recorded at the end of infiltration, and the timer was started on the anesthesia machine. The surgeons were allowed to give the surgical incision after 15 min of drug infiltration. Fentanyl 0.5 µg/kg IV was administered intraoperatively as a rescue medication in response to patient movement or complaints of pain with a visual analogue scale (VAS > 3). The medication might be repeated as necessary. The anesthesia procedure was converted to general anesthesia at any timepoint intraoperatively if the sedation score became ≥ 5. Following the completion of surgery, patients were sent to the recovery room for two h in order to monitor their vital signs and detect any potential side effects. In order to manage pain after surgery during the first 24 h, patients were administered intravenous paracetamol (1 gram) if their VAS score exceeded 3.

Fig. 1.

5- Point infiltration technique. Point 1: insertion point- Anterior and superior to tragus with direction of needle as medial and lateral. Target nerve- Auriculotemporal nerve, Point 2: insertion point- Into everted tragus with direction of needle as superiorly and inferiorly. Target nerve- Auricular branch of Vagus nerve, Point 3: insertion point- Superiorly and inferiorly along the posterior sulcus with direction of needle as superiorly and inferiorly along the posterior sulcus. Field block, Point 4: insertion point- Posteriorly in auricular groove, at the level of posterior auricular ligament with direction of needle as superiorly and inferiorly along the posterior sulcus and medially. Field block, Point 5: insertion point- Posterior to lower lobe with direction of needle as superiorly along the posterior sulcus and medially. Target nerve- Greater Auricular nerve and Lesser Occipital nerves.

Data collection

Baseline data included age, gender, height, body weight, and American Society of Anesthesiologists class. The vital parameters recorded included peripheral oxygen saturation (%), heart rate (bpm), blood pressure (mm Hg), and respiratory rate (bpm), measured at arrival, after infiltration, after incision, and then at every ten-minute interval till the end of the surgery.

Intraoperative bleeding was estimated on the basis of surgical bleeding by Boezzart's scale, demonstrating 0: no bleeding, 1: slight bleeding, in which blood evacuation is not necessary; 2: slight bleeding, in which some blood should be evacuated; 3: light bleeding, in which blood should be frequently evacuated as the operative field is visible only briefly after the evacuation; 4: average bleeding, in which blood should be often evacuated as the operative field is visible only immediately after the evacuation; and 5: vigorous bleeding, in which constant blood evacuation is needed as bleeding often exceeds the evacuation, resulting in rendering the surgery nearly impossible. The surgeon used epinephrine (1:1,000)-soaked cottonoids to clear blood for better visibility of the surgical field. We documented the overall number of epinephrine (1:1,000)-soaked cottonoids utilized upon completion of the surgical procedure.

The pain score (VAS 0–10), where 0 indicates no pain, five indicates distressing pain, and ten corresponds to maximum pain, was assessed at the time of arrival on OT, at the time of incision, at the arrival of PACU, and after that at 4 h, 8 h, 12 h, 18 h, and 24 h.

The degree of sedation was evaluated using the Ramsay Sedation Score (RSS). The target sedation level was determined as a Richmond Agitation-Sedation Scale (RSS) score of 3 or higher. 1 = anxious, agitated, restless; 2 = cooperative, oriented, tranquil; 3 = responds to commands only; 4 = brisk response to a light glabellar tap or loud noise; 5 = sluggish response to a light glabellar tap or loud noise; 6 = no response was measured at arrival, at the time of incision, after 15 min, at arrival in PACU, after 4 h, 8 h, and 12 h. Surgeon satisfaction was evaluated at the end of the surgery according to a 5-point Likert scale (5: excellent, 4: good, 3: satisfactory, 2: poor, 1: very poor).

Time for the demand for first rescue analgesia and net consumption of analgesic at the end of the first 24 h were recorded.

Hypotension was defined as a decrease in systolic blood pressure by 30% or more. Intraoperatively, Ephedrine 10 mg IV was administered in the event of hypotension. Bradycardia was defined as a heart rate below 45 beats per minute, and if it occurred, atropine 1 mg was given intravenously.

During the perioperative period, any observed occurrences of nausea, vomiting, bradycardia, tachycardia, and hypotension were documented as adverse effects.

Outcome measures

The primary objective of this study was to compare the intraoperative bleeding at the surgical site with the use of 0.5 µg/kg and 1 µg/kg DEX with 2% lidocaine used for local infiltration. The secondary objectives were time of first analgesia requirement, degree of sedation, surgeon’s satisfaction, and intraoperative hemodynamics.

Statistical analysis

Considering the large effect size as per Cohen's guidelines, the effect size was 0.8 at the 5% level of significance and 95% power. Based on this, sample size was calculated using the equation as Sakpal (2010). The sample size required was 41 subjects per group. Considering 10% follow-up loss, the minimum sample size required was 45 subjects per group. Hence, the total sample size was 90 subjects.

The data was analyzed utilizing SPSS Statistics (version 21.0, SPSS Inc.). Categorical variables are presented in the format of a frequency table. Continuous variables are presented in the form of mean ± SD or median (1Q, 3Q). The demographic data was evaluated using appropriate statistical tests such as chi-square, student t-test, and Mann-Whitney U test. The bleeding score, surgeon satisfaction score, sedation score, pain score, requirement of initial analgesia, and hemodynamics were assessed using the Mann-Whitney U test. Chi-square tests were used to analyze the amount of rescue analgesia required, patient movements throughout surgery, and number of adrenaline-soaked gauze calculations. A P value less than 0.05 was considered to be statistically significant.

RESULTS

A total of one hundred and ten patients were enrolled in the current study, of which ninety-eight were randomized in two groups of forty-nine each. All the patients received the study treatment according to the allocated group. Four patients in each group were not included in the final analysis due to conversion to general anesthesia or abandonment of surgery, as can be seen in the CONSORT diagram (Fig. 2).

Fig. 2.

CONSORT diagram showing the flow of participants through each stage of the randomized trial. CONSORT: Consolidated Standards for Reporting of Trials.

Baseline parameter

No differences in baseline parameters were apparent in the two groups, while the total duration of surgery was also comparable in both groups (Table 1).

Baseline Characteristics of Study Population

Primary and secondary end points

The bleeding score was significantly greater in the DEX 0.5 group (3.21 ± 0.727) compared to the DEX 1.0 group (1.43 ± 0.661) (P value < 0.001) (Fig. 3). The intraoperative requirement for epinephrine-soaked cottonoids was greater in DEX 0.5 Group when compared to DEX 1.0 group. In the DEX 0.5 group, the majority of patients required 12 cottonoids soaked in epinephrine throughout the surgery, but in the DEX 1.0 group, most patients did not require any cottonoids. (Table 2).

Fig. 3.

Figure showing mean bleeding score with Standard deviation of the two groups. DEX 0.5 group: patients received 10 ml of 2% lignocaine with 0.5 µg/kg dexmedetomidine (n = 45), DEX 1.0 group: patients received 10 ml of 2% lignocaine with 1 µg/kg dexmedetomidine (n = 45). DEX: dexmedetomidine.

Distribution of Subjects on Different Variables Over Groups

The time to first analgesic requirement was also significantly higher in the DEX 1.0 group (6.95 h ± 1.03) than the DEX 0.5 group (6.5 h ± 1.24). The total requirement of rescue analgesia in 24 h was comparable in both groups. Intraoperatively, the requirement of sedation was fulfilled in the DEX 1.0 group by having a higher mean RSS at all time points (values). At 15 min from infiltration (P value < 0.001) and at the end of surgery (P value 0.001), the RSS was significantly higher in the DEX 1.0 group. Within the DEX 0.5 group, there was not a single patient who exhibited fewer than three instances of movement during the surgical procedure. The maximum number of patients in this group moved at least twelve times, which was 26.1% of total patients enrolled in that group. In the DEX 1.0 group, 82.4% moved for less than three times during the entire duration of surgery.

Due to the administration of a greater dose of DEX, patients in the DEX 1.0 group were anticipated to have hypotension and bradycardia. Although the heart rate was consistently lower compared to the baseline (DEX 0.5 group 80.57 ± 10.17 and DEX 1.0 group 81.71 ± 9.3) at all time periods, the observed difference was not statistically significant in either of the groups at any timepoint. None of the patients required rescue medication in both groups. The baseline systolic blood pressure was comparable in both groups. At infiltration, there was a significant increase in systolic blood pressure observed in both groups. After 15 min at incision, the systolic blood pressure again became comparable to baseline in both groups. The decrease seen in the DEX 1.0 group was significantly greater at all observed time points (Fig. 4). Overall, the decrease was within 20% of baseline, so none of the patients required any rescue medication in either group. Both groups exhibited similar values for all other measured parameters (such as respiratory rate and oxygen saturation) at all time intervals. The surgeon satisfaction score assessed at the end of surgery was 4.34 ± 0.745 and 3.47 ± 0.5 in groups B and A, respectively, and the difference is highly significant (P < 0.001). No differences were identified in the incidence of any complication.

Fig. 4.

Figure showing mean systolic blood pressure of the two groups with standard deviation over timeline. SBP: systolic blood pressure, DEX 0.5 group: patients received 10 ml of 2% lignocaine with 0.5 µg/kg dexmedetomidine (n = 45), DEX 1.0 group: patients received 10 ml of 2% lignocaine with 1 µg/kg dexmedetomidine (n = 45). SBP: systolic blood pressure, DEX: dexmedetomidine.

DISCUSSION

In this trial, we selected two different doses of DEX as an adjuvant for infiltration for nerve block. The study found that using DEX at a dose of 1 µg/kg, in addition to 2% lignocaine, for infiltration anesthesia in tympanoplasty surgery was more effective than using a dose of 0.5 µg/kg DEX in achieving a bloodless surgical field (with a bleeding score of 1.43 ± 0.661 compared to 3.21 ± 0.727). The higher dose of DEX resulted in significantly improved intraoperative sedation scores and surgeon satisfaction without causing any hemodynamic instability. The incidence of hypotension and bradycardia was low in both groups, and it was not clinically significant as no rescue medication was required. The additional advantage, apart from creating a bloodless field, was achieved due to the better sympatholytic effect of the higher dose used for local infiltration.

An optimal anesthetic method for tympanoplasty should maximize the visibility of the surgical area while avoiding significant low blood pressure and enabling real-time monitoring of facial nerve activity. Additionally, it should minimize the risk of severe coughing during recovery and postoperative nausea and vomiting. Historically, adrenaline has been employed in conjunction with local anesthetics to reduce blood loss and prolong the analgesic effects by inducing local vasoconstriction. However, it lacks any inherent sedative or analgesic effects. Moreover, it can be associated with serious side effects like anxiety, dizziness, palpitations, sweating, shortness of breath, flushing, chest pain, tremors, and nausea [12]. Furthermore, it is not recommended for individuals with cardiac disorders, uncontrolled hypertension, and hyperthyroidism. As a substitute or supplement to adrenaline, α2 agonists like clonidine and DEX have been explored in microsurgeries [13-15]. A systemic review and meta-analysis was done by Tirupathi et al. [16] on the use of clonidine versus adrenaline as an adjunct to lignocaine for nerve block for dental surgeries. The majority of studies included in the review reported a significant drop in mean heart rate, systolic blood pressure, diastolic blood pressure, and mean arterial pressure during the intraoperative period when clonidine was administered as a vasoconstrictor. Conflicting results were however reported for the duration of anesthesia, where clonidine increased the duration on subjective assessment (numbness) in comparison to epinephrine, while epinephrine increased the duration when measured objectively (pin prick). This might be due to the difference in the number of studies that evaluated subjective and objective parameters. The results of this meta-analysis pointed towards the use of clonidine with lignocaine for nerve blocks in hypertensive patients undergoing dental surgeries.

The efficacy of intravenous DEX in reducing surgical hemorrhage in microscopic procedures has been evaluated satisfactorily. The results were encouraging with clear surgical field, adequate sedation, and duration of analgesia. Nalawade et al. [4] discovered that the combination of lignocaine and DEX provided superior surgical conditions, a quicker onset of anesthesia, extended pain relief, and lower hemodynamic values in comparison to the combination of lignocaine and adrenaline [2]. The analgesic and vasoconstrictor effects of DEX have been investigated in similar procedures by delivering it through various routes of administration. Motlagh et al. [17] used different intravenous doses of DEX and observed improved surgical field with higher doses, but also increased chances of bradycardia. But, in our trial, we found better visibility of the surgical field without clinically significant bradycardia. The possible reason could be the local infiltration as the route of administration, as it generates a low steady plasma concentration. We compared two distinct doses of DEX, hypothesizing that the lower dose could produce local effects, whereas systemic benefits might require a higher dose to build up drug plasma concentration. Both effects are critical for achieving favorable results for the surgeon and the patient. No study has been found that measures the plasma level achieved after local infiltration of DEX. Wu et al. [18] conducted a comparison of the effects of different routes of DEX and found that the intravenous route yielded the most favorable surgical field compared to the nasal or oral route. The peak plasma concentration in individuals administered with intravenous and nasal methods was attained at 13.2 min and 70.3 min, respectively. However, the oral route did not result in the attainment of the peak plasma concentration [18].

The other potential advantage of DEX observed in our trial was controlled hypotension without bradycardia, thereby decreasing bleeding and further increasing the efficacy of DEX. It produces hypotension at low plasma concentrations and hypertension with bradycardia at higher plasma concentrations. The infiltration route creates possibly a low plasma concentration, thus direct α2 receptor activation and thereby reflex baroreceptor reflex are avoided. No respiratory depression was observed, which becomes clinically more significant in tympanoplasty, where the patient's face and upper body are under drape.

The typical discomforts experienced by patients undergoing tympanoplasty include surgical noise, anxiety, vertigo, lower back pain, claustrophobia, and ear pain. DEX induces a sleep-wake cycle that closely resembles the natural physiological pattern while also producing sedation that can be easily interrupted. Analgesic action of DEX has central and local perineural mechanisms with prolonged hyperpolarization of sensory C fibers and motor A fibers. Additionally, our findings indicate that administering a higher dose of DEX resulted in a significantly prolonged period of pain relief, improved sedation scores, and reduced patient movement during surgery. The aforementioned attributes of DEX resulted in increased patient satisfaction.

Compared to adrenaline when DEX was used as an adjuvant, the additional benefit of procedural sedation produced a smooth and calm patient, as observed by our sedation score. Both the patient and the surgeon expressed a high level of satisfaction with the use of DEX, which effectively provided comprehensive anesthesia by infiltration route.

Our technique of local infiltration was standardized and robust, thereby reducing the incidence of operator bias. We administered the recommended higher dosage of DEX in the infiltration block without observing any adverse reactions.

Unfortunately, we were unable to quantify the plasma levels of DEX at various time intervals due to its unavailability at our institution. While we have established a uniform approach for the local infiltration technique, it is important to note that operator bias cannot be completely eradicated.

Future prospect

Comparative studies that focus on the pharmacokinetics and pharmacodynamics of DEX administered via infiltration can be conducted. Additional experiments, including incremental doses of DEX, are needed to determine the ideal dosage that achieves the most favorable surgical environment while minimizing adverse effects.

Thus, 2% lignocaine with 1 µg/kg of DEX is sufficient for infiltration for tympanoplasty under monitored anesthesia care. It can provide utmost patient and surgeon satisfaction.

Notes

FUNDING

None.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

DATA AVAILABILITY STATEMENT

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

AUTHOR CONTRIBUTIONS

Writing - original draft: Richa Singh, Annu Choudhary, Swati Singh. Writing - review & editing: Annu Choudhary, Harsh Kumar. Conceptualization: Richa Singh, Annu Choudhary, Swati Singh. Data curation: Richa Singh, Annu Choudhary. Formal analysis: Richa Singh, Annu Choudhary, Swati Singh. Methodology: Richa Singh, Annu Choudhary, Swati Singh, Harsh Kumar. Visualization: Annu Choudhary, Harsh Kumar. Investigation: Richa Singh, Annu Choudhary, Swati Singh, Harsh Kumar. Software: Swati Singh, Harsh Kumar. Supervision: Richa Singh, Annu Choudhary, Swati Singh. Validation: Swati Singh, Harsh Kumar.

References

1. Malhotra M, Malhotra R, Varshney S, Priya M, Bhardwaj A, Tyagi A, et al. A historical review of Indian perspectives on techniques of tympanoplasty. Int J Otolaryngol 2020;2020:1408270.
2. Parikh DA, Kolli SN, Karnik HS, Lele SS, Tendolkar BA. A prospective randomized double-blind study comparing dexmedetomidine vs. combination of midazolam-fentanyl for tympanoplasty surgery under monitored anesthesia care. J Anaesthesiol Clin Pharmacol 2013;29:173–8.
3. Naaz S, Ozair E. Dexmedetomidine in current anesthesia practice- a review. J Clin Diagn Res 2014; 8: GE01-4. Erratum in: J Clin Diagn Res 2022;16:ZZ01.
4. Nalawade SH, Nilesh K, Kumar CDM, Punde PA, Patil PB. A clinical comparative study of dexmedetomidine as an adjuvant to 2% plain lignocaine and 2% lignocaine with 1:200,000 adrenaline as local anesthetic agents for surgical removal of impacted mandibular third molars. Natl J Maxillofac Surg 2021;12:255–61.
5. Swami S, Kokane D, Joshi VS, Sirat VS. Study to evaluate and compare the effect of addition of dexmedetomidine to lignocaine 2% + adrenaline on hemodynamic stability by parameters like heart rate, blood pressure, SpO2 and bleeding in ear surgery. MedPulse International Journal of Anesthesiology 2022;23:26–31.
6. Dogan R, Erbek S, Gonencer HH, Erbek HS, Isbilen C, Arslan G. Comparison of local anesthesia with dexmedetomidine sedation and general anesthesia during septoplasty. Eur J Anaesthesiol 2010;27:960–4.
7. Ouchi K, Koga Y, Nakao S, Sugiyama K. Dexmedetomidine dose-dependently enhances local anesthetic action of lidocaine. J Oral Maxillofac Surg 2014;72:474–80.
8. Ren Y, Wei M, Liu H, Wang Y, Chen H, Li Z, et al. Efficacy and safety of dexmedetomidine as an adjuvant to local wound infiltration anaesthesia: A meta-analysis with trial sequential analysis of 23 randomised controlled trials. Int Wound J 2021;18:32–48.
9. Salahudheen A, Haidry N, Ahmad S, Choudhary S, Mokhtar EA, Shivhare P. Efficacy of pre-emptive infiltration of dexmedetomidine with a local anaesthetic on postoperative pain in maxillofacial trauma management under general anaesthesia: a prospective study. Ann Maxillofac Surg 2024;14:33–9.
10. Singh S, Prasad C. Post-operative analgesic effect of dexmedetomidine administration in wound infiltration for abdominal hysterectomy: A randomised control study. Indian J Anaesth 2017;61:494–8.
11. Sola C, Dadure C, Choquet O, Capdevila X. Nerve blocks of the face. NYSORA [Internet]. 2023 [cited 2023 Jun 5]. Available from https://www.nysora.com/nerve-blocks-face/#toc_REGIONAL-NERVE-BLOCKS-OF-THE-EXTERNAL-EAR.
12. Greene BHC, Lalonde DH, Seal SKF. Incidence of the “adrenaline rush” and vasovagal response with local anesthetic injection. Plast Reconstr Surg Glob Open 2021;9e3659.
13. Shende S, Chakravarti N, Raghuvanshi SK, Shidhaye RV. Comparison of dexmedetomidine and clonidine as an adjuvant to lignocaine with adrenaline in infiltration anesthesia for tympanoplasty. Anaesth Pain & Intensive Care 2016;20:309–14.
14. Agrawal N, Sinha S, Kadni RR, Ramkrishnan S. Effectiveness of low dose dexmedetomidine for an oligaemic field in middle ear surgery: a randomized control trial. J Clin of Diagn Res 2022;16:19–23.
15. Raghuwanshi SK, Chakravarty N, Asati DP, Bankwar V. Use of clonidine as an adjuvant to infiltration anesthesia in tympanoplasty: a randomized double blind study. Indian J Otolaryngol Head Neck Surg 2014;66:57–62.
16. Tirupathi SP, Afnan L, Alahari S, Challa R. Clonidine versus adrenaline as an adjunct to lignocaine on hemodynamic parameters during nerve block for third molar surgical removal - a systematic review and meta-analysis. Ann Maxillofac Surg 2022;12:203–11.
17. Motlagh SD, Rokhtabnak F, Ghodraty MR, Delarestaghi MM, Saadat S, Araghi Z. Effect of different loading doses of dexmedetomidine on controlled hypotension and the incidence of bradycardia during rhinoplasty: a clinical trial. Anesth Pain Med 2021;11e118857.
18. Wu J, Han Y, Lu Y, Zhuang Y, Li W, Jia J. Perioperative low dose dexmedetomidine and its effect on the visibility of the surgical field for middle ear microsurgery: a randomised controlled trial. Front Pharmacol 2022;13:760916.

Article information Continued

Fig. 1.

5- Point infiltration technique. Point 1: insertion point- Anterior and superior to tragus with direction of needle as medial and lateral. Target nerve- Auriculotemporal nerve, Point 2: insertion point- Into everted tragus with direction of needle as superiorly and inferiorly. Target nerve- Auricular branch of Vagus nerve, Point 3: insertion point- Superiorly and inferiorly along the posterior sulcus with direction of needle as superiorly and inferiorly along the posterior sulcus. Field block, Point 4: insertion point- Posteriorly in auricular groove, at the level of posterior auricular ligament with direction of needle as superiorly and inferiorly along the posterior sulcus and medially. Field block, Point 5: insertion point- Posterior to lower lobe with direction of needle as superiorly along the posterior sulcus and medially. Target nerve- Greater Auricular nerve and Lesser Occipital nerves.

Fig. 2.

CONSORT diagram showing the flow of participants through each stage of the randomized trial. CONSORT: Consolidated Standards for Reporting of Trials.

Fig. 3.

Figure showing mean bleeding score with Standard deviation of the two groups. DEX 0.5 group: patients received 10 ml of 2% lignocaine with 0.5 µg/kg dexmedetomidine (n = 45), DEX 1.0 group: patients received 10 ml of 2% lignocaine with 1 µg/kg dexmedetomidine (n = 45). DEX: dexmedetomidine.

Fig. 4.

Figure showing mean systolic blood pressure of the two groups with standard deviation over timeline. SBP: systolic blood pressure, DEX 0.5 group: patients received 10 ml of 2% lignocaine with 0.5 µg/kg dexmedetomidine (n = 45), DEX 1.0 group: patients received 10 ml of 2% lignocaine with 1 µg/kg dexmedetomidine (n = 45). SBP: systolic blood pressure, DEX: dexmedetomidine.

Table 1.

Baseline Characteristics of Study Population

Characteristics DEX 0.5 group (n = 45) DEX 1.0 group (n = 45) P value
Age (yr) 29 ± 13 29 ± 13 0.472
M/F 17/28 21/24 0.527
ASA physical status (n)
 I 31 (68.9) 28 (62.0)
 II 14 (31.1) 17 (37.8)
Weight (kg) 57 ± 10 59 ± 10 0.253
Surgery duration (min) 87 ± 16 77 ± 19 0.002

Values are presented as mean ± SD, number only, or number (%). DEX 0.5 group: patients received 10 ml of 2% lignocaine with 0.5 µg/kg dexmedetomidine, DEX 1.0 group: patients received 10 ml of 2% lignocaine with 1 µg/kg dexmedetomidine. ASA: American Society of Anesthesiology, DEX: dexmedetomidine.

Table 2.

Distribution of Subjects on Different Variables Over Groups

Variable Subcategory Groups
P value
DEX 0.5 group (n = 45) DEX 1.0 group (n = 45)
Time to first analgesic requirement 6.5 ± 1.24 6.95 ± 1.03 0.029
Surgeon satisfaction score 3.47 ± 0.5 4.34 ± 0.745 < 0.001
Frequency of Paracetamol (g required) 1 0 9 (19.6) 0.852
2 45 (97.8) 35 (76.1)
Number of movements 0 0 4 (8.7) 0.258
1 0 3 (6.5)
2 0 14 (30.4)
3 1 (2.2) 14 (30.4)
4 1 (2.2) 3 (6.5)
5 9 (19.6) 6 (13.3)
6 10 (21.7) 0
7 10 (21.7) 0
8 12 (26.1) 0
9 3 (6.5) 0
No. of epinephrine soaked cottoniods 0 0 19 (41.3) 0.968
1 0 2 (4.3)
2 0 7 (15.2)
3 1 (2.2) 3 (6.5)
4 1 (2.2) 6 (13)
5 1 (2.2) 5 (10.9)
6 4 (8.7) 1 (2.2)
7 0 1 (2.2)
8 9 (19.6) 0
9 1 (2.2) 0
10 12 (26.1) 0
11 2 (4.3) 0
12 12 (26.1) 0
14 3 (6.5) 0
Call for Anaesthesiologist No 46 (100.0) 43 (93.5) -

Values are presented as mean ± SD or number (%). DEX 0.5 group: patients received 10 ml of 2% lignocaine with 0.5 µg/kg dexmedetomidine, DEX 1.0 group: patients received 10 ml of 2% lignocaine with 1 µg/kg dexmedetomidine. DEX: dexmedetomidine.